FDA’s OTC Monograph Meetings Guidance Is Final

FDA finalised “Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs” on 14 July 2026, four and a half years after the February 2022 draft. It shared the day's Federal Register with another long-awaited finalisation whose notice described three years of revisions as “a few”. This notice took the other approach: it says what changed.

What this guidance is

OTC monograph drugs — the sunscreens, antacids, and cough medicines sold without approved applications — are regulated under section 505G of the FD&C Act, the framework the CARES Act created in March 2020. Section 505G(l) requires FDA to issue guidance on the procedures and principles for formal meetings with sponsors and requestors; this document is that requirement discharged. A “formal meeting” here covers any requested meeting for advice on the studies needed to support a monograph order request, on monograph drug development, or on other matters of nonprescription drug regulation — in any format, from in-person to written response only.

The boundary is drawn in the same paragraph: none of this applies to nonprescription products being developed for approval under section 505 — NDA and ANDA meetings have their own guidances. And the timing is not incidental. Under OMUFA II, the user-fee reauthorization enacted 12 November 2025, FDA agreed to meeting-management goals for fiscal years 2026 through 2030; the final guidance incorporates them.

What changed from the draft

The notice's account of the revision runs to a full paragraph of specifics — worth listing, because each one answers a comment or closes a gap the draft left open.

• IND advice is now in scope. On its own initiative, FDA extended the guidance to meetings about clinical investigations conducted under an IND where the IND's purpose is to support a determination that a monograph condition is generally recognized as safe and effective.
• Type Y meetings, counted. Commenters worried FDA was limiting them. The final explains there are three categories of Type Y meeting, and FDA will generally grant one per category over the course of a monograph order development program.
• Formats rebuilt. The meeting formats — in-person face-to-face, virtual face-to-face, teleconference, and written response only — were revised to better accommodate virtual and hybrid meetings.
• Vocabulary fixed. “OTC monograph industry working group” confused commenters; it is now “joint meeting requester”.
• Confidentiality clarified. The final says when information submitted for a formal meeting is treated as confidential and when FDA would post information connected to one.
• A path for follow-ups. FDA explained how requesters can submit clarifying questions on meeting minutes or a written response after receiving them.

The quiet contrast

Notices of availability are boilerplate-heavy documents, and nothing obliged FDA to enumerate its edits here — the psychedelics finalisation published the same morning shows the floor: comments were considered, “a few revisions were made”, read the documents yourself. For a sponsor deciding whether a finalisation changes their meeting strategy, the difference between those two notices is the difference between reading three pages and running a document comparison. It costs the agency a paragraph.

The standard caveat still applies: guidance binds nobody. The final “does not establish any rights for any person and is not binding on FDA or the public”, and an alternative approach remains open if it satisfies the statute and regulations. What finalisation changes, as ever, is what a review division will cite back to you.